| Literature DB >> 24809370 |
Tomohiro Yoshimoto1, Kazufumi Matsushita1.
Abstract
We propose two types of allergic response: IgE-dependent and IgE-independent, and designate these as 'acquired-type allergy' and 'innate-type allergy', respectively. IL-33 stimulates both innate (basophils, mast cells, or group 2 innate lymphoid cells) and acquired (Th2 cells) allergy-related cells to induce and/or augment Th2 cytokine production, which leads to eosinophilic inflammation in vivo. Thus, IL-33 is an essential regulator for both 'innate-type allergy' and 'acquired-type allergy', and might be an attractive therapeutic target for allergic diseases.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24809370 DOI: 10.2332/allergolint.13-RA-0657
Source DB: PubMed Journal: Allergol Int ISSN: 1323-8930 Impact factor: 5.836